Digestive system neuroendocrine neoplasm

This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…

This early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…

This study tests whether adding a radioactive drug (177Lu-DOTA-TATE) to standard therapy (octreotide) helps control advanced neuroendocrine tumors of the gut or pancreas better than standard therapy alone. About 240 newly diagnosed patients with slow-growing but high-burden tumor…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This study tests whether removing as much tumor as possible through surgery before giving a targeted radioactive drug (Lutetium Lu 177 dotatate) works better for people with slow-growing neuroendocrine tumors that have spread to the liver. Six adults with grade 1 or 2 tumors will…

This study tests a new drug that delivers radiation directly to cancer cells carrying a protein called DLL3, found in small cell lung cancer and other solid tumors. The trial enrolls 138 adults whose cancer has progressed after at least two prior treatments. The goal is to check …

This study tests a new drug called [212Pb]VMT-α-NET, which delivers a powerful type of radiation (alpha particles) directly to tumor cells that have a specific marker (SSTR2). The trial includes 300 adults with advanced neuroendocrine tumors or meningioma that cannot be removed b…

This study tests whether adding a targeted drug (sirolimus) to a standard hormone-blocking injection (octreotide) can better control advanced neuroendocrine tumors of the stomach, intestines, or pancreas. About 298 adults with tumors that cannot be removed by surgery will receive…

This study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors (GEP-NETs) that have grown after prior radiation therapy. The trial has two parts: first finding the right dose, then comparing RYZ101 to standard treatments like everolimus or sunitinib. Abou…

This study is tracking 50 adults with neuroendocrine tumors who are receiving peptide receptor radionuclide therapy (PRRT). Researchers are collecting data on patient characteristics, treatment responses, survival, and side effects. The goal is to better understand who benefits f…

This early-phase study tests whether adding focused external radiation (SBRT) before a standard radioactive drug therapy (177Lu-DOTATATE) is safe and effective for people with large, inoperable neuroendocrine tumors of the digestive system. About 15 adults whose tumors have grown…

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to check the drug's safety and see if it can shrink or control tumors. About 156 participants will receive the drug intravenousl…

This Phase 3 trial tests whether adding chemotherapy (capecitabine and temozolomide) to standard radiation therapy (PRRT) helps people with advanced neuroendocrine tumors of the stomach, pancreas, or intestines that show high activity on FDG PET scans. The study plans to enroll 1…

This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrin…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study will analyze medical records of over 4,000 people newly diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the U.S. Researchers aim to understand which treatments are used, in what order, and how long patients stay on them. The goal is to describe…

This study looks at how factors like age, sex, tumor grade, and location influence how well treatments work for people with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Researchers will follow 450 patients to see how long their disease stays und…

This study aims to find out what factors might increase the risk of developing neuroendocrine tumors, a rare type of cancer. Researchers will analyze health records from over 14,000 people in Bavaria, Germany, looking at things like smoking, diabetes, and even depression. The goa…

This study at Strasbourg University Hospital will check the nutritional status of 100 adults with gastroenteropancreatic neuroendocrine tumors. Researchers want to see if malnutrition is linked to worse outcomes. The goal is to understand whether improving nutrition could help pa…

This study is looking at people with a rare type of digestive system cancer called GEP-NET who are receiving a targeted radiation therapy (PRRT). Researchers will use special PET-MRI scans and artificial intelligence to find patterns that predict how well the treatment works. The…